This inventor holds 1 USPTO granted patent. Top assignee: Tasly Pharmaceutical Group Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Wei Sun and a Pharmaceutical Composition for Myocardial Ischemia.
Introduction
Wei Sun is an inventor based in Tianjin, China, associated with Tasly Pharmaceutical Group Co., Ltd. The supplied information lists 1 patent for him, concerning a pharmaceutical composition intended to prevent or treat myocardial ischemia.
Latest Patents
The patent, “Pharmaceutical Composition for Treating Myocardial Ischemia and Preparation Method Therefor,” describes a composition containing 250–700 parts by weight of Salvia miltiorrhiza, 50–150 parts of Radix notoginseng, 3–9 parts of synthetic borneol, and 25–100 parts of ranolazine. It also describes using the composition to prepare a medicine for the prevention and/or treatment of myocardial ischemia.
Career Highlights
The available information connects Sun’s patent work with Tasly Pharmaceutical Group Co., Ltd. The invention combines traditional medicinal materials with ranolazine in a proposed formulation for myocardial ischemia.
Collaborations
The supplied data identifies He Sun and Kaijing Yan as Sun’s coworkers. It does not specify their roles in the patent or the nature of their collaboration.
Conclusion
Wei Sun’s listed patent focuses on a multi-ingredient pharmaceutical composition and its preparation for potential use against myocardial ischemia.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile